Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-24T04:02:23.287Z Has data issue: false hasContentIssue false
  • English
  • Français

Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence

Published online by Cambridge University Press:  16 April 2020

Angela J. Dean ,
James Bell ,
Macdonald J. Christie  and
Richard P. Mattick
Angela J. Dean*
Affiliation:
Department of Psychiatry, University of Queensland4029, Australia The Langton Centre, Nobbs St, Surry Hills 2010, Australia Department of Pharmacology and Medical Foundation, University of Sydney2006, Australia
James Bell
Affiliation:
The Langton Centre, Nobbs St, Surry Hills 2010, Australia
Macdonald J. Christie
Affiliation:
Department of Pharmacology and Medical Foundation, University of Sydney2006, Australia
Richard P. Mattick
Affiliation:
National Drug and Alcohol Research Centre, University of New South Wales, 2052, Australia
*
*Corresponding author. Mater Centre for Service Research in Mental Health, Mater Misercordiae Health Services, Raymond Terrace, South Brisbane QLD 4001, Australia. Email address: [email protected]
Get access

Abstract

Research suggests that buprenorphine may possess antidepressant activity. The Beck Depression Inventory was completed at baseline and 3 months by heroin dependent subjects receiving either buprenorphine or methadone maintenance as part of a larger, pre-existing, double blind trial conducted by NDARC (Australia). Depressive symptoms improved in all subjects, with no difference between methadone and buprenorphine groups, suggesting no differential benefit on depressive symptoms for buprenorphine compared to methadone.

Keywords

BuprenorphineAntidepressantDepressionOpioid dependenceMethadone
Type
Short communication
Information
European Psychiatry , Volume 19 , Issue 8 , December 2004 , pp. 510 - 513
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ball, JCRoss, A.Treatment success: association with patient baseline, program elements, and in-treatment process. In: Ball, JCRoss, A, editors. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991. p. 212–32.CrossRefGoogle Scholar
Beck, ATWard, CHMendelson, MMock, JErbaugh, J.An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.CrossRefGoogle ScholarPubMed
Bodkin, JAZornberg, GLLukas, SECole, JO.Buprenorphine treatment of refractory depression. J Clin Psychopharm 1995;15:49–57.CrossRefGoogle ScholarPubMed
Ciofalo, FR. Methadone inhibition of 3H-5-hydroxytryptamine uptake by synaptosomes. J Pharm Exp Ther 1974;189:83–9.Google ScholarPubMed
Darke, SHall, WWodak, AHeather, NWard, J.Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the opiate treatment index. Brit J Add 1992;87:733–42.CrossRefGoogle ScholarPubMed
Darke, SRoss, J.The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 2000;95:407–17.CrossRefGoogle ScholarPubMed
De Montis, GMDevoto, PTagliamonte, A.Possible antidepressant activity of methadone. Eur J Pharmacol 1982;79:145–6.CrossRefGoogle ScholarPubMed
Dilsaver, SC. The pathophysiologies of substance abuse and affective disorders: an integrative model? J Clin Psychopharmacol 1987;7:1–0.Google Scholar
Emrich, HMVogt, PHerz, A.Possible antidepressant effects of opioids: action of buprenorphine. Ann N Y Acad Sci 1982;398:108–12.CrossRefGoogle ScholarPubMed
Fischer, BLGRehm, JDaniel, NMedved, W.Comparing opiate users in methadone treatment with untreated opiate users: results of a follow-up study with a Toronto opiate user cohort. Can J Pub Health 1999;90:299–303.CrossRefGoogle ScholarPubMed
Goldstein, JA. Methadone for depression. Biol Psychiat 1984;19: 1272–3.Google ScholarPubMed
Gomez-Flores R, Weber, R.Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immu-nopharmacology 2000;48:145–56.Google Scholar
Harris, DSMendelson, JELin, ETUpton, RAJones, RT.Pharmacoki-netics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. Clin Pharmacokin 2004;43:329–40.CrossRefGoogle ScholarPubMed
Huang, PKehner, GCowan, ALiu-Chen, L.Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbu-prenorphine is a potent opioid agonist. J Pharm Exp Ther 2001;297: 688–95.Google ScholarPubMed
Kosten, TRMorgan, CKosten, TA.Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Ab Treat 1990;7: 51–4.CrossRefGoogle ScholarPubMed
Lewis, JWRance, MJSanger, DJ.The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello, NK, editor. Advances in substance abuse. Connecticut: JAI Press; 1983. p. 103–54.Google Scholar
Ling, WCharuvastra, CCollins, JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicentre, randomised clinical trial. Addiction 1998;93:475–86.CrossRefGoogle Scholar
Mague, SDPliakas, AMTodtenkopf, MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharm Exp Ther 2003;305:323–30.CrossRefGoogle ScholarPubMed
Mattick, RPAli, RWhite, JM, O’Brien S, Wolk, SDanz, C.Buprenor-phine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003;98: 441–52.CrossRefGoogle Scholar
Pani, PPMaremmani, IPirastu, RTagliamonte, AGessa, GL.Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000;60:39–50.CrossRefGoogle ScholarPubMed
Petry, NMBickel, WKBadger, GJ.A comparison of four buprenor-phine dosing regimens using open-dosing procedures: is twice weekly dosing possible? Addiction 2000;95:1069–77.CrossRefGoogle Scholar
Rothman, RBGorelick, DAHeishman, SJ, et al. An open-label study of a functional opioid k antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000;18:277–81.CrossRefGoogle Scholar
Rounsaville, BJWeissman, MMCrits-Christoph, KWilber, CKleber, H.Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psych 1982; 39:151–6.CrossRefGoogle ScholarPubMed
Sbrenna, SMarti, MMorari, M, et al. Modulation of 5-hydroxy-tryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol 2000;130:425–33.CrossRefGoogle ScholarPubMed
Strain, ECStitzer, MLBigelow, GE.Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis 1991;179: 215–21.CrossRefGoogle ScholarPubMed
Tejedor-Real P, Mico, JAMaldonado, RRoques, BPGibert-Rahola, J.Implication of endogenous opioid system in the learned helplessness model of depression. Pharm Biochem Behav 1995;52:145–52.Google Scholar
Submit a response

Comments

No Comments have been published for this article.